Thursday, December 26, 2024
12/26/2024
Project Summary/Abstract Myeloproliferative neoplasms (MPNs) are chronic blood disorders that that can cause severe symptoms and early death. New treatments have become available that help ameliorate symptoms, but they do not reliably slow or halt disease progression. We seek to better understand what drives disease development and progression in MPNs, so that we can develop better therapies for patients with these diseases. Our preliminary data indicates that the NFkB pathway is abnormally activated in MPNs. We hypothesize that NFkB pathway signaling contributes to the development of MPNs. Therefore, we have proposed a combination of mouse and human studies to determine how NFkB contributes to MPN pathogenesis, and to evaluate whether inhibition of NFkB pathway signaling may have potential therapeutic benefits for MPN patients.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).